Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

Many doctors recommend routine follow-up tests for cancer patients after they’ve completed a course of treatment, with the ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

Former National Institutes of Health Director Dr. Francis Collins, who abruptly left his NIH research lab in February, fears ...

The Washington Post/ABC/Ipsos and the AP/NORC poll out in the last couple of days even show him with a 39% approval rating ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Buoyed by four $1 million donations, Trump's inaugural festivities reeled in $5.3 million from Washington state residents and businesses.

Andreas Kalcker’s appearance at the conference highlights how dangerous alternative health claims have been growing during Trump’s second term in office.